Jiaxiang Ji
Overview
Explore the profile of Jiaxiang Ji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ji J, Lai C, Ni R, Wang M, Hu H, Bian X, et al.
Transl Androl Urol
. 2025 Feb;
14(1):81-90.
PMID: 39974803
Background: The treatment paradigm of metastatic bladder cancer has remained largely unchanged for decades and the prognosis is extremely poor. This study aimed to evaluate the role of cystectomy in...
2.
Ji J, Wang F, Lai C, Wang M, Hu H, Xu K, et al.
Sci Rep
. 2025 Feb;
15(1):5977.
PMID: 39966479
This study was designed to evaluate the impact of upper tract urothelial carcinoma (UTUC) history on prognosis in patients with non-muscle-invasive bladder cancer (NMIBC) receiving intravesical chemotherapy. We conducted a...
3.
Lai C, Ji J, Bian X, Xu T, Hu H
Transl Androl Urol
. 2025 Jan;
13(12):2827-2832.
PMID: 39816231
Background: Aggressive angiomyxoma (AAM) is a rare benign mesenchymal tumor known for its aggressive behavior and high recurrence rates, with male cases of AAM being less frequently reported. This study...
4.
Ji J, Lai C, Zhang X, Hu H
Front Immunol
. 2025 Jan;
15:1501415.
PMID: 39763683
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of systemic cancer therapy. During disinhibiting the antitumor responses of immune system, ICIs may also cause unique immune-related adverse events (irAEs) which...
5.
Wang M, Lai J, Ji J, Tang X, Hu H, Wang Q, et al.
Beijing Da Xue Xue Bao Yi Xue Ban
. 2024 Dec;
56(6):1069-1074.
PMID: 39690772
Objective: To assess health related quality of life (HRQOL) in patients with kidney stones and to predict risk factors for reduced HRQOL in the patients by the Chinese version of...
6.
Ji J, Ramasamy J, Nazzaro L, Kohut J, Ezzat A
Sci Rep
. 2024 Nov;
14(1):29147.
PMID: 39587205
The Mid-Atlantic region is set to be one of the first and largest contributors to the offshore wind energy goals of the United States. Yet, the same region is home...
7.
Lai C, Ji J, Wang M, Hu H, Xu T, Hu H
Transl Androl Urol
. 2024 Oct;
13(9):1823-1834.
PMID: 39434743
Background: Radical cystectomy (RC) patients are at significant risk for venous thromboembolism (VTE). Current predictive models, such as the Caprini risk assessment (CRA) model, have limitations. This research aimed to...
8.
Ji J, Lai C, Lai S, Xu T, Hu H
Transl Androl Urol
. 2024 Oct;
13(9):2160-2165.
PMID: 39434729
Background: Ureteroarterial fistula (UAF) is a rare yet potentially life-threatening condition, which is challenging for urologists. It is traditionally treated by open surgical repair and endovascular repair. Intraureteral repair (IUR)...
9.
Hu H, Lai S, Ni R, Wang M, Lai C, Ji J, et al.
Transl Androl Urol
. 2024 Jul;
13(6):983-993.
PMID: 38983475
Background: Cisplatin-based combination chemotherapy alone is currently considered the standard of care for patients with metastatic upper tract urothelial carcinoma (mUTUC). However, less research has been done on the efficacy...
10.
Wang M, Lai C, Ji J, Hu H, Ni R, Liu J, et al.
Urolithiasis
. 2024 Jul;
52(1):103.
PMID: 38960942
Kidney stones and infections significantly affect patients' health-related quality of life (HRQOL); however, the relationship between urinary tract infections (UTIs) and HRQOL in patients with kidney stones remains unclear. This...